Legacy Financial Advisors Inc. Reduces Position in Pfizer Inc. (NYSE:PFE)

Legacy Financial Advisors Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 22.5% during the 4th quarter, Holdings Channel reports. The fund owned 40,436 shares of the biopharmaceutical company’s stock after selling 11,757 shares during the period. Legacy Financial Advisors Inc.’s holdings in Pfizer were worth $1,073,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the 4th quarter valued at $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the 4th quarter worth $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer during the 4th quarter worth $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PFE. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group reduced their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $31.07.

Pfizer Trading Up 3.0 %

Shares of PFE opened at $22.50 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The firm has a market cap of $127.61 billion, a price-to-earnings ratio of 15.96, a PEG ratio of 0.64 and a beta of 0.67. The business’s fifty day moving average is $25.42 and its 200-day moving average is $26.51.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.